Ting-Yi Lin,Seyedamirhosein Motamedi,Susanna Asseyer,Claudia Chien,Shiv Saidha,Peter A Calabresi,Kathryn C Fitzgerald,Sara Samadzadeh,Pablo Villoslada,Sara Llufriu,Ari J Green,Jana Lizrova Preiningerova,Axel Petzold,Letizia Leocani,Elena Garcia-Martin,Celia Oreja-Guevara,Olivier Outteryck,Patrick Vermersch,Laura J Balcer,Rachel Kenney,Philipp Albrecht,Orhan Aktas,Fiona Costello,Jette Frederiksen,Antonio Uccelli,Maria Cellerino,Elliot M Frohman,Teresa C Frohman,Judith Bellmann-Strobl,Tanja Schmitz-Hübsch,Klemens Ruprecht,Alexander U Brandt,Hanna G Zimmermann,Friedemann Paul

Abstract:Background and objectives: Retinal optical coherence tomography (OCT) provides promising prognostic imaging biomarkers for future disease activity in multiple sclerosis (MS). However, raw OCT-derived measures have multiple dependencies, supporting the need for establishing reference values adjusted for possible confounders. The purpose of this study was to investigate the capacity for age-adjusted z scores of OCT-derived measures to prognosticate future disease activity and disability worsening in people with MS (PwMS). Methods: We established age-adjusted OCT reference data using generalized additive models for location, scale, and shape for peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell-inner plexiform layer (GCIP) thicknesses, involving 910 and 423 healthy eyes, respectively. Next, we transformed the retinal layer thickness of PwMS from 3 published studies into age-adjusted z scores (pRNFL-z and GCIP-z) based on the reference data. Finally, we investigated the association of pRNFL-z or GCIP-z as predictors with future confirmed disability worsening (Expanded Disability Status Scale score increase) or disease activity (failing of the no evidence of disease activity [NEDA-3] criteria) as outcomes. Cox proportional hazards models or logistic regression analyses were applied according to the original studies. Optimal cutoffs were identified using the Akaike information criterion as well as location with the log-rank and likelihood-ratio tests. Results: In the first cohort (n = 863), 172 PwMS (24%) had disability worsening over a median observational period of 2.0 (interquartile range [IQR]:1.0-3.0) years. Low pRNFL-z (≤-2.04) were associated with an increased risk of disability worsening (adjusted hazard ratio (aHR) [95% CI] = 2.08 [1.47-2.95], p = 3.82e-5). In the second cohort (n = 170), logistic regression analyses revealed that lower pRNFL-z showed a higher likelihood for disability accumulation at the two-year follow-up (reciprocal odds ratio [95% CI] = 1.51[1.06-2.15], p = 0.03). In the third cohort (n = 78), 46 PwMS (59%) did not maintain the NEDA-3 status over a median follow-up of 2.0 (IQR: 1.9-2.1) years. PwMS with low GCIP-z (≤-1.03) had a higher risk of showing disease activity (aHR [95% CI] = 2.14 [1.03-4.43], p = 0.04). Compared with raw values with arbitrary cutoffs, applying the z score approach with optimal cutoffs showed better performance in discrimination and calibration (higher Harrell's concordance index and lower integrated Brier score). Discussion: In conclusion, our work demonstrated reference cohort-based z scores that account for age, a major driver for disease progression in MS, to be a promising approach for creating OCT-derived measures useable across devices and toward individualized prognostication.

Olfactory threshold as a biomarker of long-term relapse activity in multiple sclerosis

Long-term clinical, imaging and cognitive outcomes association with MS immunopathology

Prognostic immunological markers in patients with relapsing-remitting multiple sclerosis: a prospective magnetization transfer brain imaging study (P3117)

Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting

Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years

The effects of cognition, quality of life, and fatigue on olfactory function in patients with multiple sclerosis

Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT

Novel biomarkers and interferon signature in secondary progressive multiple sclerosis

Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis

Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis

Immune-inflammatory, Metabolic and Hormonal Biomarkers Are Associated with the Clinical Forms and Disability Progression in Patients with Multiple Sclerosis: A Follow-Up Study.

Predicting clinical progression and cognitive decline in patients with relapsing-remitting multiple sclerosis: a 6-year follow-up study

Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity

Retinal thinning differentiates treatment effects in relapsing multiple sclerosis below the clinical threshold

Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis

Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness z Scores

Olfactory dysfunction in patients with multiple sclerosis; A systematic review and meta-analysis

Factors Associated With Persisting Olfactory Dysfunction After COVID‐19

The effect of alemtuzumab on neurodegeneration in relapsing-remitting multiple sclerosis: A five-year prospective mono-center study

Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis